Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Gymnema Sylvestre vs Orforglipron: Gymnema Sylvestre has the stronger overall evidence (5.5 vs 5.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Gymnema Sylvestre wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Gymnema Sylvestre and Orforglipron have evidence — compare verdict strength side-by-side.
200-400mg standardized extract (≥25% gymnemic acids) 1-2x daily, or 2-4g dried leaf
with-meals
Standardized extract (≥25% gymnemic acids)
INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.
any
Oral tablet (investigational)
8-12 weeks
Immediate-2 weeks
8-12 weeks
Days
Weeks to months
Months (titrated)
Throughout use
Especially during dose escalation
The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis.
Phytotherapy research : PTR (2021) · Meta analysis
Significant reductions in fasting blood glucose and HbA1c versus control
The effects of Gymnema Sylvestre supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults: A systematic review and meta-analysis.
Phytotherapy research : PTR (2023) · Meta analysis
Reductions in fasting glucose and improvements in lipid profile
A systematic review of Gymnema sylvestre in obesity and diabetes management.
Journal of the science of food and agriculture (2014) · Systematic review
Possible benefits for glycemic control and body weight
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1).
N Engl J Med (2025) · Rct · n=3127
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
N Engl J Med (2025) · Rct · n=559
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (2026) · Rct · n=962
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
Gymnema Sylvestre has a higher evidence score (5.5/10 vs 5.5/10) and wins in 2 of 3 categories.
For manage blood sugar, Gymnema Sylvestre has a higher relevance score (82 vs 70).
No known interactions between Gymnema Sylvestre and Orforglipron have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.